SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Women & Children First – Politician rediscovers Chivalry in Gardasil Debate

By Leave a Comment

ComeLook.org
10 September 2010
Although it’s very unusual for an ambitious politician to tell a potential voter to not communicate with him (“not to waste politician’s time”), in Ireland at least, highlighting the “not appropriate” subject of vaccine safety can provoke such a response.

When a campaigner wrote two short emails to a Wexford local politician in late 2008 raising concerns about the HPV vaccine Gardasil and suggesting he do some research into the associated side effects, the local politician’s response was “Please refrain from sending me any further misinformed and unrequested junk spam”.

Mairead Hilliard, of Irish Vaccine Informed Parents, wrote to Counciller Joe Ryan (now Mayor of Wexford, pop 18000), after she noticed that he had joined an online Facebook group campaigning for reinstatement of the cervical cancer mass vaccination program in Ireland.

Th1 cytokine patterns in cervical human papillomavirus infection.

By Leave a Comment

PubMed.gov

Clin Diagn Lab Immunol. 1999 Sep;6(5):751-5.

Scott M, Stites DP, Moscicki AB.

Department of Pediatrics, University of California, San Francisco, California 94143, USA. mscott@itsa.ucsf.edu
Abstract

The host’s immune response to cervical human papillomavirus (HPV) infection is poorly understood. In a longitudinal cohort of women with cervical HPV infections, defined by PCR-based HPV DNA testing, we used exfoliated cervical cells and reverse transcription-PCR to examine the cervical mucosal mRNA expression of cytokines involved in regulating cell-mediated immunity. We identified seven HPV-positive subjects who were found to have cleared their HPV infections 4 months later. In all seven, a T-helper type 1 (Th1) cytokine pattern (expression of gamma interferon and absence of interleukin-4) preceded clearance. The more variable cytokine patterns seen in HPV-negative subjects suggest that the Th1 pattern in the women with subsequent clearance was a response to the HPV infection.

Schoolgirl chlamydia increase blamed on cancer jab

By 1 Comment

Deadline Scotland

By Martin Graham

CHLAMYDIA is on the rise among Scottish schoolgirls, and the increase has been blamed on a new jab to prevent cervical cancer.

Figures released by the NHS show that cases of the sexually transmitted disease in girls under 15 have risen by over a third, with doctors treating almost two new cases of the infection every week, mostly girls who fall within the age group offered the jab.

The trend matches the timing of the introduction of the human papillomavirus (HPV) jab for all girls aged between 12 and 17 in September 2008.

Reports summarize human papillomavirus research from University of Michigan

By 1 Comment

NewsRx

September 6, 2010

Investigators publish new data in the report ‘Examining future adolescent human papillomavirus vaccine uptake, with and without a school mandate.’ In this recent report published in the Journal of Adolescent Health, researchers in the United States conducted a study “To develop a model of adolescent (HPV) human papillomavirus vaccine utilization that explored future HPV vaccination rates, with and without a school mandate, for the vaccine at middle school entry. A dynamic, population-based, compartmental model was developed that estimated over a 50-year time horizon HPV vaccine uptake among female adolescents living in the United States.”

'We will continue to sell our patented drugs with India-specific pricing'

By 1 Comment

The Times of India

September 8, 2010

MSD India’s managing director KG Ananthakrishnan spoke to ET’s Khomba Singh on future strategy and shared his views on the Indian government’s proposals on contentious issues such as compulsory licensing, capping FDI in the sector and reviewing of certain sections of Indian patent laws. Excerpts:

Global drugmakers have lobbied hard for review of controversial Section 3(d) of Indian patent laws and patent linkages. MNCs, including Merck, are yet to publicly voice views on the proposal being evaluated by the government?

News

Videos

Contact